Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life populationZoé Van de Wyngaert, Eileen M. Boyle, Sarah Barbieux et al.|British Journal of Haematology|2019Cited by 29
Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of FranceZoé Van de Wyngaert, Eileen M. Boyle, Benjamin Carpentier et al.|Blood|2018Cited by 6
Combination of CD20xCD3 Bispecific Antibodies with Ibrutinib and Lenalidomide Shows Efficacy in Relapsed/ Refractory CNS LymphomaSandy Amorim, Laurent Pascal, Benjamin Carpentier et al.|Blood|2024Cited by 2
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B PhenotypeAlexandre Willaume, Laurent Pascal, Mourtaza Karimdjee et al.|Blood|2022Cited by 0
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysisAlexandre Willaume, Laurent Pascal, Loïc Chartier et al.|Hematological Oncology|2023Cited by 0